Summary
Amgen Inc. announced on March 12, 2010, the successful issuance and sale of $1 billion in senior notes. This offering comprises $300 million of 4.50% Senior Notes due 2020 and $700 million of 5.75% Senior Notes due 2040. The net proceeds from this transaction are approximately $988 million and are earmarked for general corporate purposes. Investors should note that the net proceeds are allocated to a range of uses, including working capital, capital expenditures, debt service, share repurchases under existing programs, and strategic business initiatives such as acquisitions and licensing. This debt issuance is a significant financial maneuver that will impact Amgen's capital structure and future financial flexibility.
Key Highlights
- 1Amgen Inc. issued and sold a total of $1 billion in senior notes.
- 2The offering consisted of $300 million in 4.50% Senior Notes due 2020.
- 3The offering also included $700 million in 5.75% Senior Notes due 2040.
- 4Net proceeds from the offering are approximately $987,956,000 after deducting discounts and expenses.
- 5Proceeds are designated for general corporate purposes, including working capital, capital expenditures, debt service, and share repurchases.
- 6Funds will also support strategic initiatives such as acquisitions and licensing activities.
- 7The notes are unsecured and rank equally with other senior unsecured indebtedness of Amgen.